Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

References

• Henderson DA. The eradication of smallpox – an overview of the past, present, and future. Vaccine 2011;29(Suppl 4):D7-9
   PubMedGoogle Scholar
• Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346(17):1300-8
   PubMed Web of Science ®Google Scholar
• WHO Advisory Committee on variola virus research. Report of a WHO Committee, WHO/CDS/CSR/2000.1. Available from: www.who.int/csr/resources/publications/viral/whocdscsr20001.pdf Geneva, Switzerland; 1999
   Google Scholar
• WHO Advisory Committee on variola virus research. Report of the second meeting. WHO/CDS/CSR/EDC/2001/17. Available from: www.who.int/csr/resources/publications/viral/WHO_CDS_CSR_EDC_2001_17/en/2014(06/2014) Geneva: Switzerland; 2001
   Google Scholar
• WHO Advisory Committee on Variola Virus Research. WHO Advisory Committee on variola virus research. Report of the third meeting, WHO/CDS/CSR/GAR/2002/3. Available from: www.who.int/csr/resources/publications/viral/WHO_CDS_CSR_GAR_2002_3/en/2014(06) Geneva Switzerland; 2002
   Google Scholar
• LeDuc JW, Damon I, Relman DA, et al. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg Infect Dis 2002;8(7):743-5
   PubMed Web of Science ®Google Scholar
• Aebersold P. FDA experience with medical countermeasures under the animal rule. Adv Prev Med 2012;2012:507571
   PubMedGoogle Scholar
• Parker S, Siddiqui AM, Painter G, et al. Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics. Viruses 2010;2(9):1918-32
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Kern ER. Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246. Viruses 2010;2(12):2681-95
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Collins DJ, Wan WB, et al. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(2):404-12
   PubMed Web of Science ®Google Scholar
• Rice AD, Adams MM, Lampert B, et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2011;3(2):63-82
   PubMed Web of Science ®Google Scholar
• Parker S, Chen NG, Foster S, et al. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – an animal model of smallpox. Antiviral Res 2012;94(1):44-53
   PubMed Web of Science ®Google Scholar
• Duraffour S, Mertens B, Meyer H, et al. Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals. PLoS One 2013;8(2):e55808
   Web of Science ®Google Scholar
• Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005;191(3):396-9
   PubMed Web of Science ®Google Scholar
• Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005;49(9):3724-33
   PubMed Web of Science ®Google Scholar
• Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections. Viruses 2010;2(12):2740-62
   PubMed Web of Science ®Google Scholar
• Randhawa P, Farasati NA, Shapiro R, Hostetler KY. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother 2006;50(4):1564-6
   PubMed Web of Science ®Google Scholar
• Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002;46(4):991-5
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Lampert B, Collins DJ, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010;202(10):1492-9
   PubMed Web of Science ®Google Scholar
• Hostetler KY. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2010;2(10):2213-25
   PubMed Web of Science ®Google Scholar
• Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol 1996;50(6):1502-10
   PubMed Web of Science ®Google Scholar
• Uwai Y, Ida H, Tsuji Y, et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007;24(4):811-15
   PubMed Web of Science ®Google Scholar
• Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59(3):163-71
   PubMed Web of Science ®Google Scholar
• Painter W, Robertson A, Trost LC, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012;56(5):2726-34
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013;369(13):1227-36
   PubMed Web of Science ®Google Scholar
• Trost LC, Tippin T, Anderson MT, Painter WP. Compromised renal function does not affect the pharmacokinetics of CMX001 in patients with severe double-stranded DNA virus infections. Poster Presented at: 50th ICAAC Meeting. Boston, MA
   Google Scholar
• Vistide (cidofovir injection) prescribing information. Available from: www.gilead.com/∼/media/Files/pdfs/medicines/other/vistide/vistide.pdf 2010. [Last accessed 12 December 2013]
   Google Scholar
• Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46(8):2381-6
   PubMed Web of Science ®Google Scholar
• James SH, Price NB, Hartline CB, et al. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother 2013;57(7):3321-5
   PubMed Web of Science ®Google Scholar
• Schnepf N, Dhedin N, Mercier-Delarue S, et al. Dynamics of cytomegalovirus populations harbouring mutations in genes UL54 and UL97 in a haematopoietic stem cell transplant recipient. J Clin Virol 2013;58(4):733-6
   PubMed Web of Science ®Google Scholar
• Bravo FJ, Bernstein DI, Beadle JR, et al. Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Antimicrob Agents Chemother 2011;55(1):35-41
   PubMed Web of Science ®Google Scholar
• Hayes K, Gibas H. Placental cytomegalovirus infection without fetal involvement following primary infection in pregnancy. J Pediatr 1971;79(3):401-5
   PubMed Web of Science ®Google Scholar
• Griffiths PD, Baboonian C. A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br J Obstet Gynaecol 1984;91(4):307-15
   PubMedGoogle Scholar
• Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Virol 2000;74(15):6808-20
   PubMed Web of Science ®Google Scholar
• Spano LC, Lima Pereira FE, Gomes da Silva Basso N, Mercon-De-Vargas PR. Human cytomegalovirus infection and abortion: an immunohistochemical study. Med Sci Monit 2002;8(6):BR230-5
   PubMedGoogle Scholar
• Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012;18(5):731-8
   PubMed Web of Science ®Google Scholar
• Florescu DF, Qiu F, Mercer DF, et al. Risk factors for systemic Candida infections in pediatric small bowel transplant recipients. Pediatr Infect Dis J 2012;31(2):120-3
   PubMed Web of Science ®Google Scholar
• Murakami Y, Eki T, Yamada M, et al. Species-specific in vitro synthesis of DNA containing the polyoma virus origin of replication. Proc Natl Acad Sci USA 1986;83(17):6347-51
   PubMed Web of Science ®Google Scholar
• Fairman M, Prelich G, Tsurimoto T, Stillman B. Identification of cellular components required for SV40 DNA replication in vitro. Biochim Biophys Acta 1988;951(2-3):382-7
   PubMedGoogle Scholar
• Weinberg DH, Collins KL, Simancek P, et al. Reconstitution of simian virus 40 DNA replication with purified proteins. Proc Natl Acad Sci USA 1990;87(22):8692-6
   PubMed Web of Science ®Google Scholar
• Farasati NA, Shapiro R, Vats A, Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005;79(1):116-18
   PubMed Web of Science ®Google Scholar
• Bernhoff E, Gutteberg TJ, Sandvik K, et al. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008;8(7):1413-22
   PubMed Web of Science ®Google Scholar
• Rinaldo CH, Gosert R, Bernhoff E, et al. 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother 2010;54(11):4714-22
   PubMed Web of Science ®Google Scholar
• Mommeja-Marin H, Marty FM, Boeckh M, et al. MX001, a novel broad spectrum antiviral, may mitigate signs of BK virus (BKV) associated bladder and kidney end-organ damage (P010.034). Presented at: XXIV International Congress of the Transplantation Society. Berlin, Germany
   Google Scholar
• Jiang ZG, Cohen J, Marshall LJ, Major EO. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures. Antimicrob Agents Chemother 2010;54(11):4723-32
   PubMed Web of Science ®Google Scholar
• Gosert R, Rinaldo CH, Wernli M, et al. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob Agents Chemother 2011;55(5):2129-36
   PubMed Web of Science ®Google Scholar
• Patel A, Patel J, Ikwuagwu J. A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010;65(12):2697-8
   PubMed Web of Science ®Google Scholar
• Lederman ER, Davidson W, Groff HL, et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012;206(9):1372-85
   PubMed Web of Science ®Google Scholar
• Buller RML, Palumbo GJ. Poxvirus pathogenesis. Microbiol Rev 1991;55(1):80-122+IIIA
   PubMedGoogle Scholar
• Cohen JI, Davila W, Ali MA, et al. Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001. J Infect Dis 2012;205(5):794-7
   PubMed Web of Science ®Google Scholar
• Papanicolaou G, Grimley M, Morrison M, et al. Pre-engraftment initiation of Brincidofovir (CMX001) in hematopoietic cell transplant recipients is supported by lack of myeloid toxicity. PH-P474. Presented at: 40th Annual Meeting of the European Group for Blood and Marrow Transplantation. Milan, Italy
   Google Scholar